Is androgen excess masked in alopecia areata patients: a retrospective data analysis of 1,587 patients
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Introduction
Alopecia areata (AA) is a common non-scarring
inflammatory hair loss. AA is considered to be a T cell
dependent autoimmune disease in which a complex interplay
between genetic and epigenetic factors leads to a
heterogenous clinical presentation and disease progression.
Current evidence suggests that environmental triggers, such
as emotional stress, increase the release of stress induced
corticotropin-relasing hormone (CRH) thus altering the
hypothalamic pituitary axis (HPA) as well as the hair follicle
microenvironment, potentially playing a role in the severity or
course of AA(Ito,Kim,Islam).

Table 1.

Table 2a-b.
A.

Materials & Methods
A retrospective study was conducted using an institutional review
board approved database of 1,587 AA patients diagnosed at the
Cleveland Clinic Department of Dermatology from 2005 to 2015.
Inclusion criteria included available laboratory hormonal levels
and/or past gynecological history. Patients were categorized into
one of four AA subtypes: patchy alopecia, alopecia areata ophiasis
subtype, alopecia totalis, or alopecia universalis. To compare the
prevalence of hormonal dysfunction compared to the general
population levels of polycystic ovarian syndrome (PCOS), 95%
confidence intervals for the prevalence were created, and tests
against 6% (the upper limit for PCOS prevalence in the general
population) were performed. The distribution of dysfunction types
were compared using one-sample goodness of fit chi-square tests.
Pearson chi-square tests were used to compare groups defined by
diagnosis or dysfunction on various characteristics. One-sided onesample t-tests compared diagnosis groups against the lower normal
limit for vitamin D (20ng/mL). Analyses were performed using
SAS software (version 9.3; Cary, NC).

Comparisons of distribution of dysfunction overall and by subtype. For all subtypes, statistically significant
results were observed (p<0.001 for all except FFA (p=0.001)).

B.

•A total of 226 alopecia areata patients demonstrated either
objective laboratory evidence of hormonal imbalance (i.e.
abnormal circulating hormone levels), and/or history of
ovarian dysfunction, and/or clinical evidence of androgen
excess.
•In comparison to the prevalence of PCOS in the normal
population, hormonal and endocrine dysfunction is
approximately 2.4 times more prevalent in the AA patient
population.
•Androgen Excess/PCOS was the most significant
dysfunction in all AA subtypes.

•Adult acne, hirsutism, PCOS, and ovarian cysts were
significant clinical makers that predicted androgen excess.

Objective
The objective of this study was to assess for the prevalence of
a hormonal and/or endocrine disorder among AA patients.

Results

Table 3.

Conclusions
Conclusions
The data in the present study revealed an increased prevalence
of sex hormone dysfunction among alopecia areata patients.
This suggests that altered sex hormone balance may be
involved in modulating AA. From this study, however, we
were unable to ascertain a causal relationship with AA onset or
progression. As sex hormone imbalance may play a role in the
course of AA, we suggest androgen excess screening (total
testosterone, free testosterone, free testosterone %, DHEAS
and androstenedione) in patients that have menstrual
irregularities, trouble conceiving, PCOS, ovarian cysts, and/or
have clinical evidence of elevated androgens (hirsutism or
adult acne). Further studies will be needed to elucidate the
benefit of anti- androgen therapy in the clinical management
of AA patients.
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